Exhibit 16.1
March 28, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated March 28, 2017, of KemPharm, Inc. and are in agreement with the statements contained in paragraphs 2, 3, 4 and 5 under "(a)" on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
In addition, we have no basis to agree or disagree with other statements of the registrant contained in "(b)" on page 2 of the above referenced filing.
/s/ Ernst & Young LLP
Certified Public Accountants